MTOR and mantle cell lymphoma: These cells also are sensitive to inhibition of CDK4/6 and mTOR, two other kinases that play a role in MCL pathogenesis and therapy permitting evaluation of potentially the most effective drug combination in the in vitro and in vivo preclinical models.